Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 13 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk RecurrenceRecruitingNCT06682728Phase 2
• Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)Not yet recruitingNCT06681285Phase 2
• Single cEll pRofiling PErsistaNce To ImmuNothErapyRecruitingNCT06680739Phase 2
• Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal CarcinomaNot yet recruitingNCT06680115Phase 2
• Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingNCT06680050Phase 2
• Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsRecruitingNCT06673628Phase 2
• A Phase I/II Study of IVONESCIMAB in Recurrent GlioblastomaRecruitingNCT06672575Phase 1/2
• Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.RecruitingNCT06670911Phase 2
• Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentRecruitingNCT06669572Phase 2
• CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRCNot yet recruitingNCT06665087Phase 2
• Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTTRecruitingNCT06664996Phase 2
• Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).RecruitingNCT06663098Phase 2
• Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung CancerRecruitingNCT06659042Phase 2
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsRecruitingNCT06657144Phase 1
• Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerRecruitingNCT06656598Phase 2
• Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
• A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
• CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRCNot yet recruitingNCT06652412Phase 2
• NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV MelanomaRecruitingNCT06651151Phase 2
• NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
• Study of LM-299 in Subjects Advanced Malignant TumorsRecruitingNCT06650566Phase 1/2
• Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICCNot yet recruitingNCT06648525Phase 2
• Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）RecruitingNCT06647680Phase 2
• Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)Not yet recruitingNCT06647563Phase 3
• Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 2
• A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingNCT06646276Phase 3
• A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingNCT06642792Phase 1/2
• TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingNCT06640582Phase 1/2
• Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical OutcomesRecruitingNCT06640283Phase 2
• Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingNCT06637306Early Phase 1
• Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Phase 2
• Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue SarcomaRecruitingNCT06637007Phase 2
• All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II TrialRecruitingNCT06636981Phase 2
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 2
• Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid TumorsRecruitingNCT06635785Phase 1/2
• Perioperative Therapies in Locally Advanced Unresectable Gastric CancerRecruitingNCT06630130Phase 2
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruitingNCT06627647Phase 3
• Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaRecruitingNCT06624475Phase 2
• Study to ONO-4538 in Patients With Rhabdoid TumorRecruitingNCT06622941Phase 2
• TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
• Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)Not yet recruitingNCT06621095Phase 2
• Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingNCT06620822Phase 2
• A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)RecruitingNCT06618664Phase 3
• Local Injection and Systemic Therapy in the Treatment of NSCLC.Not yet recruitingNCT06618391Phase 2
• A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCRecruitingNCT06617416Phase 3
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
• Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical TrialsRecruitingNCT06612632Phase 1/2
• A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract CancersRecruitingNCT06611345Not applicable
• Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVERecruitingNCT06607276Phase 2
• The Efficacy and Safety of Benmelstobart for GC/EGCNot yet recruitingNCT06603974Not applicable
• Surgery for Relapsed Ovarian Cancer in PrecisionNot yet recruitingNCT06602063Phase 1/2
• Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Phase 2
• Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal CancerNot yet recruitingNCT06599775Phase 2
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingNCT06594991Phase 2
• Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsNot yet recruitingNCT06592625Phase 2
• Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)RecruitingNCT06592599Phase 2
• 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerRecruitingNCT06592326Phase 3
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2
• A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06589778Phase 1/2
• BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06588335Phase 2
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell CarcinomaRecruitingNCT06585410Phase 3
• A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruitingNCT06584071Phase 1/2
• Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerRecruitingNCT06584032Phase 3
• Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06583083Phase 2
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingNCT06581406Phase 2/3
• Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung CancerNot yet recruitingNCT06580665Not applicable
• Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingNCT06577961Phase 1/2
• Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)RecruitingNCT06571708Phase 2
• Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCANot yet recruitingNCT06569225Phase 2
• A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingNCT06567782Phase 2
• Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaRecruitingNCT06567314Phase 2
• Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal CancerRecruitingNCT06566755Phase 3
• Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1
• A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingNCT06564298Phase 2
• Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung CancerRecruitingNCT06562920Phase 2
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Phase 3
• Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial CancerRecruitingNCT06561308Phase 2
• Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsRecruitingNCT06561087Phase 2
• CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Phase 1
• An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecruitingNCT06560112Phase 2
• GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.RecruitingNCT06558773Phase 2
• Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaRecruitingNCT06558227Phase 2
• OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd TrialRecruitingNCT06558214Phase 2
• EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaRecruitingNCT06556563Phase 3
• A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System LymphomaRecruitingNCT06556199Phase 1/2
• A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric CancerRecruitingNCT06555471Phase 2
• Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRCRecruitingNCT06551207Not applicable
• A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
• Oral Topotecan With Toripalimab for Patients With Endometrial CancerNot yet recruitingNCT06548763Phase 2
• Exploratory Platform Research on Precision Therapy of Advanced Pancreatic CancerRecruitingNCT06547736Phase 2
• Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer StudyRecruitingNCT06547203Phase 2
• Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1
• A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or AblationNot yet recruitingNCT06546280Phase 2
• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)RecruitingNCT06545682Phase 1
• ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingNCT06543836Phase 2
• External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/2
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARCRecruitingNCT06542588Phase 2
• Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian CancerNot yet recruitingNCT06542549Phase 3

← Immune Checkpoint Inhibitors overview